IDH1 and acute myeloid leukemia: Unfortunately, a phase I study conducted to determine safety, tolerability, pharmacokinetics, pharmacodynamics, and preliminary clinical efficacy in patients with IDH1 mutation in advanced AML showed a low overall response rate even at the highest dose tested (NCT03127735).